Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iminostilbene SCHEMBL29926907 | 0.75 | MAPT (1.00) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL3585935 | 0.74 | GAA (0.37) | MAPTGAA | |
| Iminostilbene SCHEMBL5063042 | 0.73 | MAPT (0.94) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| Iminostilbene SCHEMBL9685179 | 0.73 | MAPT (0.94) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL367140 | 0.68 | MAPT (0.64) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL367512 | 0.68 | MAPT (0.64) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL5161 | 0.67 | ALOX5 (0.59) | MAPTGAA | |
| SCHEMBL4651 | 0.67 | NOX1 (0.59) | MAPTGAARAB9ASMN1; SMN2 | |
| SCHEMBL15124521 | 0.67 | — | — | |
| SCHEMBL688577 | 0.67 | NPC1 (0.50) | MAPTGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 755 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301187-B1 | PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) | NOVO NORDISK AS (DK) | 2005-07-06 | — | — | EP | claimed |
| WO-2024151809-A1 | INHIBITORS OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE 2 (BMPR2) AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024145273-A2 | N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE | SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-4392430-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | Yale University (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4392168-A1 | IONIC LIQUID-BASED COMPOSITE MEMBRANES USING FUNCTIONAL CROSS-LINKERS | The Regents of the University of Colorado, a body corporate (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024124172-A1 | COMPOSITIONS AND METHODS FOR STIMULATING AND/OR ENHANCING EXERCISE MOTIVATION AND/OR PHYSICAL PERFORMANCE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240181438-A1 | UNSYMMETRICAL N-HETEROCYCLIC CARBENE CATALYSTS AND METHODS USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240181067-A1 | TARGETED BIFUNCTIONAL DEGRADERS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-06 | — | — | US | disclosed |
| WO-2024112744-A1 | CATALYSTS AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-1999048878-A1 | HETEROCYCLIC COMPOUNDS REGULATING CLOTTING | NOVO NORDISK A/S (DK) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999046244-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046237-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046236-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999045013-A1 | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1999-09-10 | — | — | WO | disclosed |
| WO-1999040062-A1 | HYDRAZONE DERIVATIVES | NOVO NORDISK A/S (DK) | 1999-08-12 | — | — | WO | disclosed |
| WO-1999015529-A1 | MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998040385-A1 | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1998-09-17 | — | — | WO | disclosed |
| WO-1997039748-A1 | MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997040017-A2 | MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240181067-A1 | TARGETED BIFUNCTIONAL DEGRADERS AND METHODS USING SAME | UCHL1, ADAM10, JMJD7 | MAPT 571/4885GAA 25/4885RAB9A 1717/4885 |
| US-20240181438-A1 | UNSYMMETRICAL N-HETEROCYCLIC CARBENE CATALYSTS AND METHODS USING SAME | NDC1, NUDC, NSFL1C | MAPT 4618/4885GAA 3539/4885RAB9A 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.